A relationship is considered to be modest if it is less than significant under the preceding definition. *Modest. Significant. Writing Group Disclosures Continued Writing Group Member Employment Research Grant Other Research Support Speakers Bureau/ Honoraria Expert Witness Ownership Interest Consultant/ Advisory Board Other Reviewer Disclosures Reviewer Employment Research Grant Other Research Support Speakers Bureau/ Honoraria Expert Witness Ownership Interest Consultant/ Advisory Board Other Mark J. Alberts Hartford HealthCare None None Genentech (speakers bureau) None None None None Joseph P. Broderick University of Cincinnati NIH (trial) ; NIH (investigator) Genentech (PRISMS) ; Genentech (TNK) None None None None None (Continued) Powers et al 2019 Guidelines for Management of AIS e401 Colin P. Derdeyn University of Iowa None None None None Pulse therapeutics* Penumbra* None Marc Fisher Beth Israel Deaconess Medical Center None None None None None None American Heart Association Karen L. Furie Rhode Island Hospital None None None None None None None Philip B. Gorelick Michigan State University None None None Employer received compensation for expert witness work None IMPACT clinical trial*; NeuroSpring* None Walter N. Kernan Yale University None None None None None None None Steven J. Kittner Veterans Affairs Maryland Health Care System; University of Maryland School of Medicine None None None None None None None Patrick D. Lyden Cedars-Sinai Medical Center NIH* None None None None None None Philip M. Meyers Columbia University None None None None None None None Jeffrey L. Saver UCLA None None None None Rapid Medical* Medtronic*; Stryker*; Neuravi/ Ceronovus*; Boehringer Ingelheim*; St. Jude Medical* University of California (employer)* Steven Warach University of Texas at Austin State of Texas None None Private law firm* Stock holdings in various pharma companies in a managed investment portfolio (myself)*; stock holdings in various pharma companies in a managed investment portfolio (family)* Genentech* None Lawrence R. Wechsler University of Pittsburgh None None None None None None None Babu G. Welch UT Southwestern Medical Center None None Stryker Neurovascular (speakers bureau)*; Stryker Neurovascular (honoraria)* None None Stryker Neurovascular* None This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. 